Bright Minds Biosciences Inc.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BLU.TO has a market cap of 2.47B. Regarding current trading prices, DRUG.CN is priced at $44.18, while BLU.TO trades at $19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, DRUG.CN is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MMED.NE has a market cap of 1.05B. Regarding current trading prices, DRUG.CN is priced at $44.18, while MMED.NE trades at $14.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MMED.NE's P/E ratio is -4.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MMED.NE's ROE of -0.48%. Regarding short-term risk, DRUG.CN is less volatile compared to MMED.NE. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, FRX.TO has a market cap of 249.49M. Regarding current trading prices, DRUG.CN is priced at $44.18, while FRX.TO trades at $9.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas FRX.TO's P/E ratio is -301.33. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to FRX.TO's ROE of +0.19%. Regarding short-term risk, DRUG.CN is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, CYBN.NE has a market cap of 192.18M. Regarding current trading prices, DRUG.CN is priced at $44.18, while CYBN.NE trades at $9.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas CYBN.NE's P/E ratio is -1.84. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CYBN.NE's ROE of -0.39%. Regarding short-term risk, DRUG.CN is more volatile compared to CYBN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, EPRX.TO has a market cap of 190.72M. Regarding current trading prices, DRUG.CN is priced at $44.18, while EPRX.TO trades at $5.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas EPRX.TO's P/E ratio is -5.07. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to EPRX.TO's ROE of -1.31%. Regarding short-term risk, DRUG.CN is more volatile compared to EPRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MSCL.TO has a market cap of 99.69M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MSCL.TO trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MSCL.TO's P/E ratio is 2.60. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MSCL.TO's ROE of -0.74%. Regarding short-term risk, DRUG.CN is more volatile compared to MSCL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MDNA.TO has a market cap of 78.22M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MDNA.TO trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MDNA.TO's P/E ratio is -2.70. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MDNA.TO's ROE of -1.64%. Regarding short-term risk, DRUG.CN is more volatile compared to MDNA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, GLAB.CN has a market cap of 77.86M. Regarding current trading prices, DRUG.CN is priced at $44.18, while GLAB.CN trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas GLAB.CN's P/E ratio is -20.80. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GLAB.CN's ROE of +1.38%. Regarding short-term risk, DRUG.CN is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MSET.CN has a market cap of 74.96M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MSET.CN trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MSET.CN's ROE of -3.17%. Regarding short-term risk, Volatility data is not available for a full comparison. DRUG.CN has daily volatility of 7.05 and MSET.CN has daily volatility of N/A.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, SVA.TO has a market cap of 65.70M. Regarding current trading prices, DRUG.CN is priced at $44.18, while SVA.TO trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas SVA.TO's P/E ratio is -2.22. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to SVA.TO's ROE of +2.30%. Regarding short-term risk, DRUG.CN is more volatile compared to SVA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, ONCO.CN has a market cap of 65.50M. Regarding current trading prices, DRUG.CN is priced at $44.18, while ONCO.CN trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas ONCO.CN's P/E ratio is -151.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ONCO.CN's ROE of N/A. Regarding short-term risk, DRUG.CN is more volatile compared to ONCO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, ONC.TO has a market cap of 62.22M. Regarding current trading prices, DRUG.CN is priced at $44.18, while ONC.TO trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas ONC.TO's P/E ratio is -1.76. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ONC.TO's ROE of -2.25%. Regarding short-term risk, DRUG.CN is more volatile compared to ONC.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, DTC.CN has a market cap of 54.18M. Regarding current trading prices, DRUG.CN is priced at $44.18, while DTC.CN trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas DTC.CN's P/E ratio is -11.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to DTC.CN's ROE of +1.22%. Regarding short-term risk, DRUG.CN is more volatile compared to DTC.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, PMN.TO has a market cap of 51.48M. Regarding current trading prices, DRUG.CN is priced at $44.18, while PMN.TO trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, DRUG.CN is less volatile compared to PMN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, HBP.TO has a market cap of 50.37M. Regarding current trading prices, DRUG.CN is priced at $44.18, while HBP.TO trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas HBP.TO's P/E ratio is -0.90. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to HBP.TO's ROE of +21.43%. Regarding short-term risk, DRUG.CN is more volatile compared to HBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MBX.TO has a market cap of 49.36M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MBX.TO trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MBX.TO's P/E ratio is 35.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MBX.TO's ROE of +0.07%. Regarding short-term risk, DRUG.CN is less volatile compared to MBX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, IGX.TO has a market cap of 41.92M. Regarding current trading prices, DRUG.CN is priced at $44.18, while IGX.TO trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IGX.TO's ROE of +0.93%. Regarding short-term risk, DRUG.CN is less volatile compared to IGX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BCT.TO has a market cap of 26.03M. Regarding current trading prices, DRUG.CN is priced at $44.18, while BCT.TO trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BCT.TO's P/E ratio is -0.67. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BCT.TO's ROE of +66.06%. Regarding short-term risk, DRUG.CN is more volatile compared to BCT.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, AEZS.TO has a market cap of 25.38M. Regarding current trading prices, DRUG.CN is priced at $44.18, while AEZS.TO trades at $8.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AEZS.TO's ROE of -0.83%. Regarding short-term risk, DRUG.CN is less volatile compared to AEZS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, DOSE.CN has a market cap of 24.40M. Regarding current trading prices, DRUG.CN is priced at $44.18, while DOSE.CN trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas DOSE.CN's P/E ratio is -4.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to DOSE.CN's ROE of +1.61%. Regarding short-term risk, DRUG.CN is more volatile compared to DOSE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, PHRM.CN has a market cap of 19.47M. Regarding current trading prices, DRUG.CN is priced at $44.18, while PHRM.CN trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas PHRM.CN's P/E ratio is -4.40. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PHRM.CN's ROE of -0.83%. Regarding short-term risk, DRUG.CN is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, REUN.TO has a market cap of 16.64M. Regarding current trading prices, DRUG.CN is priced at $44.18, while REUN.TO trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, DRUG.CN is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, PREV.CN has a market cap of 16.25M. Regarding current trading prices, DRUG.CN is priced at $44.18, while PREV.CN trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas PREV.CN's P/E ratio is -30.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PREV.CN's ROE of +0.22%. Regarding short-term risk, DRUG.CN is more volatile compared to PREV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, TELI.CN has a market cap of 13.77M. Regarding current trading prices, DRUG.CN is priced at $44.18, while TELI.CN trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas TELI.CN's P/E ratio is -8.83. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TELI.CN's ROE of -2.08%. Regarding short-term risk, DRUG.CN is more volatile compared to TELI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, IMV.TO has a market cap of 13.12M. Regarding current trading prices, DRUG.CN is priced at $44.18, while IMV.TO trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, DRUG.CN is more volatile compared to IMV.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, RVX.TO has a market cap of 12.76M. Regarding current trading prices, DRUG.CN is priced at $44.18, while RVX.TO trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas RVX.TO's P/E ratio is -1.12. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to RVX.TO's ROE of +0.06%. Regarding short-term risk, DRUG.CN is less volatile compared to RVX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BETR.CN has a market cap of 12.31M. Regarding current trading prices, DRUG.CN is priced at $44.18, while BETR.CN trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BETR.CN's P/E ratio is -3.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BETR.CN's ROE of +0.43%. Regarding short-term risk, DRUG.CN is more volatile compared to BETR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MDMA.CN has a market cap of 12.26M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MDMA.CN trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MDMA.CN's P/E ratio is -13.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MDMA.CN's ROE of -0.86%. Regarding short-term risk, DRUG.CN is less volatile compared to MDMA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BLAB.CN has a market cap of 11.36M. Regarding current trading prices, DRUG.CN is priced at $44.18, while BLAB.CN trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BLAB.CN's P/E ratio is -1.40. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BLAB.CN's ROE of -4.53%. Regarding short-term risk, DRUG.CN is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, TBP.TO has a market cap of 10.58M. Regarding current trading prices, DRUG.CN is priced at $44.18, while TBP.TO trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, DRUG.CN is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BIOV.CN has a market cap of 7.29M. Regarding current trading prices, DRUG.CN is priced at $44.18, while BIOV.CN trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BIOV.CN's P/E ratio is -1.25. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BIOV.CN's ROE of +4.49%. Regarding short-term risk, DRUG.CN is less volatile compared to BIOV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MCUR.CN has a market cap of 7.04M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MCUR.CN trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, DRUG.CN is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, COOL.CN has a market cap of 6.83M. Regarding current trading prices, DRUG.CN is priced at $44.18, while COOL.CN trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, DRUG.CN is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, GLOW.CN has a market cap of 6.68M. Regarding current trading prices, DRUG.CN is priced at $44.18, while GLOW.CN trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas GLOW.CN's P/E ratio is -2.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GLOW.CN's ROE of +12.80%. Regarding short-term risk, DRUG.CN is less volatile compared to GLOW.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, TRYP.CN has a market cap of 5.79M. Regarding current trading prices, DRUG.CN is priced at $44.18, while TRYP.CN trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TRYP.CN's ROE of +1.31%. Regarding short-term risk, DRUG.CN is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, APS.TO has a market cap of 5.67M. Regarding current trading prices, DRUG.CN is priced at $44.18, while APS.TO trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas APS.TO's P/E ratio is -0.04. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to APS.TO's ROE of +6.47%. Regarding short-term risk, DRUG.CN is less volatile compared to APS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, ASEP.CN has a market cap of 5.56M. Regarding current trading prices, DRUG.CN is priced at $44.18, while ASEP.CN trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas ASEP.CN's P/E ratio is -0.83. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ASEP.CN's ROE of -0.40%. Regarding short-term risk, DRUG.CN is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, CMND.CN has a market cap of 5.07M. Regarding current trading prices, DRUG.CN is priced at $44.18, while CMND.CN trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CMND.CN's ROE of -2.44%. Regarding short-term risk, DRUG.CN is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, GTTX.CN has a market cap of 4.65M. Regarding current trading prices, DRUG.CN is priced at $44.18, while GTTX.CN trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GTTX.CN's ROE of -0.60%. Regarding short-term risk, DRUG.CN is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, APLI.TO has a market cap of 4.24M. Regarding current trading prices, DRUG.CN is priced at $44.18, while APLI.TO trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas APLI.TO's P/E ratio is -1.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to APLI.TO's ROE of +0.32%. Regarding short-term risk, DRUG.CN is less volatile compared to APLI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, AWKN.NE has a market cap of 3.86M. Regarding current trading prices, DRUG.CN is priced at $44.18, while AWKN.NE trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AWKN.NE's ROE of +2.31%. Regarding short-term risk, DRUG.CN is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MYND.CN has a market cap of 3.35M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MYND.CN trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MYND.CN's ROE of +0.18%. Regarding short-term risk, DRUG.CN is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, IPCI.TO has a market cap of 2.65M. Regarding current trading prices, DRUG.CN is priced at $44.18, while IPCI.TO trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IPCI.TO's ROE of +0.16%. Regarding short-term risk, DRUG.CN is less volatile compared to IPCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, AGN.CN has a market cap of 2.32M. Regarding current trading prices, DRUG.CN is priced at $44.18, while AGN.CN trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas AGN.CN's P/E ratio is -8.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AGN.CN's ROE of +0.15%. Regarding short-term risk, DRUG.CN is more volatile compared to AGN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, MOOD.CN has a market cap of 1.85M. Regarding current trading prices, DRUG.CN is priced at $44.18, while MOOD.CN trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas MOOD.CN's P/E ratio is -6.83. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MOOD.CN's ROE of -0.28%. Regarding short-term risk, DRUG.CN is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, BRAX.CN has a market cap of 1.42M. Regarding current trading prices, DRUG.CN is priced at $44.18, while BRAX.CN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, DRUG.CN is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, ENBI.CN has a market cap of 1.39M. Regarding current trading prices, DRUG.CN is priced at $44.18, while ENBI.CN trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas ENBI.CN's P/E ratio is -2.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ENBI.CN's ROE of -1.33%. Regarding short-term risk, DRUG.CN is more volatile compared to ENBI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, HAVN.CN has a market cap of 1.15M. Regarding current trading prices, DRUG.CN is priced at $44.18, while HAVN.CN trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to HAVN.CN's ROE of +0.00%. Regarding short-term risk, DRUG.CN is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, LEXT.CN has a market cap of 1.10M. Regarding current trading prices, DRUG.CN is priced at $44.18, while LEXT.CN trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas LEXT.CN's P/E ratio is -0.52. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to LEXT.CN's ROE of -2.39%. Regarding short-term risk, DRUG.CN is more volatile compared to LEXT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, NSHS.CN has a market cap of 565136.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while NSHS.CN trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas NSHS.CN's P/E ratio is -5.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NSHS.CN's ROE of +0.09%. Regarding short-term risk, DRUG.CN is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, CHGX.CN has a market cap of 415648.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while CHGX.CN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CHGX.CN's ROE of +0.23%. Regarding short-term risk, DRUG.CN is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, CURE.CN has a market cap of 408018.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while CURE.CN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CURE.CN's ROE of -0.72%. Regarding short-term risk, DRUG.CN is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, ABRT.CN has a market cap of 372067.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while ABRT.CN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, DRUG.CN is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, WBIO.CN has a market cap of 324764.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while WBIO.CN trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas WBIO.CN's P/E ratio is 0.41. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to WBIO.CN's ROE of +0.01%. Regarding short-term risk, DRUG.CN is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, NIRV.CN has a market cap of 289398.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while NIRV.CN trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas NIRV.CN's P/E ratio is -0.30. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NIRV.CN's ROE of +0.00%. Regarding short-term risk, DRUG.CN is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, NOVA.CN has a market cap of 148319.00. Regarding current trading prices, DRUG.CN is priced at $44.18, while NOVA.CN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NOVA.CN's ROE of +0.74%. Regarding short-term risk, DRUG.CN is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, IN.TO comparison data is unavailable. Regarding current trading prices, DRUG.CN is priced at $44.18, while IN.TO trades at $4.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IN.TO's ROE of -1.57%. Regarding short-term risk, DRUG.CN is more volatile compared to IN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.

DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DRUG.CN stands at 311.20M. In comparison, TRIL.TO comparison data is unavailable. Regarding current trading prices, DRUG.CN is priced at $44.18, while TRIL.TO trades at $23.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DRUG.CN currently has a P/E ratio of -220.90, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, DRUG.CN is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.